Research programme: depression and anxiety therapies - Roche/Vernalis
Latest Information Update: 09 Apr 2021
Price :
$50 *
At a glance
- Originator Vernalis
- Developer Roche; Vernalis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis
- 03 Jul 2002 Preclinical trials in Anxiety disorders in United Kingdom (unspecified route)